A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 210 patients (estimated)
- Sponsors
- Cyclacel Pharmaceuticals, Inc.
- Tags
- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1499
- NCT Identifier
- NCT05168904
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.